Grant Playter

Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.

Various advances in contamination control are being utilized to reduce the chance pollutants contaminate a drug product.

Looking back at the biologics and large molecule drugs approved by FDA in the past year can give us hints toward what will be approved in the future.

Scaling up chromatography resins requires a thorough understanding of their intended use.

Acquisitions in the CDMO space can give us insight into a company's vision for their future.

The past year of downstream processing has brought innovations in pH sensitive antibody purification, single-use fermentation separators, and more.

As process controls adjust to a continuously shifting manufacturing landscape, implementation of information gathered from novel data analysis techniques has become a priority.

Experts weigh in on the current state of computer validation and its role in the greater regulatory landscape.

Recently released technologies aim to improve laboratory processes.

Survey respondents reflect on the state and future of the bio/pharma employment.

Recent developments in the outsourcing industry include a focus on early development services, biosimilar production, and RNA technology.

While supply chain disruptions have resulted in many alterations to workplace practices, they have also presented an opportunity to get ahead of changes to the EU’s upcoming revision of Annex 1.